Comparative Pharmacology
Head-to-head clinical analysis: LOMANATE versus VIBERZI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LOMANATE versus VIBERZI.
LOMANATE vs VIBERZI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
LOMANATE is a combination of diphenoxylate (a peripheral opioid receptor agonist that slows GI motility) and atropine (an anticholinergic that discourages abuse).
Guanylate cyclase-C agonist; increases intracellular cyclic guanosine monophosphate (cGMP) leading to activation of cystic fibrosis transmembrane conductance regulator (CFTR) ion channel, resulting in increased intestinal fluid secretion and accelerated transit.
100 mg orally twice daily
100 mg orally three times daily with meals.
None Documented
None Documented
Terminal elimination half-life is 18-24 hours in adults with normal renal function; prolonged to 40-60 hours in severe renal impairment (CrCl < 30 mL/min), requiring dose adjustment.
Terminal elimination half-life is approximately 8-9 hours, supporting twice-daily dosing.
Primarily renal (80% as unchanged drug and metabolites); biliary/fecal (15%); 5% eliminated via other routes.
Primarily fecal (approximately 95% of absorbed dose) with minimal renal excretion (<1%).
Category C
Category C
Antidiarrheal
Antidiarrheal